Three broad modalities in the natural history of vertically acquired hepatitis C virus infection - PubMed (original) (raw)
Multicenter Study
. 2005 Jul 1;41(1):45-51.
doi: 10.1086/430601. Epub 2005 May 24.
- PMID: 15937762
- DOI: 10.1086/430601
Multicenter Study
Three broad modalities in the natural history of vertically acquired hepatitis C virus infection
European Paediatric Hepatitis C Virus Network. Clin Infect Dis. 2005.
Abstract
Background: Little is known about the natural history of vertically acquired hepatitis C virus (HCV) infection.
Methods: We performed a large, multicenter, prospective study of children born to HCV-infected women in Europe. Children were considered to be infected on the basis of > or = 2 polymerase chain reaction (PCR) test results positive for HCV RNA and/or test results positive for anti-HCV antibody > 18 months after birth.
Results: Two hundred sixty-six children with vertical HCV infection were followed up until a median of 4.2 years of age (range, 3.2 months to 15.9 years of age). Twenty-six children were coinfected with human immunodeficiency virus. Hepatomegaly, the only clinical sign reported, was found in 10% of children and was significantly associated with a high proportion of abnormal alanine transaminase (ALT) levels (adjusted odds ratio [OR], 4.17; 95% confidence interval [CI], 1.67-10.42; P = .002). An estimated 21%-25% of children may have cleared the virus (i.e., had 2 consecutive PCR test results negative for HCV RNA, normal ALT levels, and no clinical signs) at a median age of 14.9 months. A high proportion of positive PCR test results obtained in the first year of life was associated with a lower likelihood of clearance (OR, 9.77; 95% CI, 2.92-32.67; P < .0001) and persistent viremia in children > 1 year old (adjusted OR, 2.92; 95% CI, 1.09-7.80; P = .03).
Conclusions: We confirm the low prevalence of HCV-related clinical signs and symptoms among vertically infected children in the first 10-15 years of life. Approximately 20% of children appear to clear the infection, 50% have evidence of chronic asymptomatic infection, and 30% have evidence of chronic active infection. Although viremia and abnormal ALT levels were associated with hepatomegaly, further investigation is necessary before these markers can be used in the clinical management of HCV infection in children.
Similar articles
- Persistence rate and progression of vertically acquired hepatitis C infection. European Paediatric Hepatitis C Virus Infection.
Tovo PA, Pembrey LJ, Newell ML. Tovo PA, et al. J Infect Dis. 2000 Feb;181(2):419-24. doi: 10.1086/315264. J Infect Dis. 2000. PMID: 10669321 - Human immunodeficiency virus infection as risk factor for mother-to-child hepatitis C virus transmission; persistence of anti-hepatitis C virus in children is associated with the mother's anti-hepatitis C virus immunoblotting pattern.
Manzini P, Saracco G, Cerchier A, Riva C, Musso A, Ricotti E, Palomba E, Scolfaro C, Verme G, Bonino F, et al. Manzini P, et al. Hepatology. 1995 Feb;21(2):328-32. Hepatology. 1995. PMID: 7843701 - Seroprevalence and mother-to-infant transmission of hepatitis C in asymptomatic Egyptian women.
Kumar RM, Frossad PM, Hughes PF. Kumar RM, et al. Eur J Obstet Gynecol Reprod Biol. 1997 Dec;75(2):177-82. doi: 10.1016/s0301-2115(97)00130-9. Eur J Obstet Gynecol Reprod Biol. 1997. PMID: 9447371 - Guidelines for the screening and follow-up of infants born to anti-HCV positive mothers.
Resti M, Bortolotti F, Vajro P, Maggiore G; Committee of Hepatology of the Italian Society of Pediatric Gastroenterology and Hepatology. Resti M, et al. Dig Liver Dis. 2003 Jul;35(7):453-7. doi: 10.1016/s1590-8658(03)00217-2. Dig Liver Dis. 2003. PMID: 12870728 Review. - Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children.
Rerksuppaphol S, Hardikar W, Dore GJ. Rerksuppaphol S, et al. J Gastroenterol Hepatol. 2004 Dec;19(12):1357-62. doi: 10.1111/j.1440-1746.2004.03463.x. J Gastroenterol Hepatol. 2004. PMID: 15610308 Review.
Cited by
- Direct-Acting Antiviral Agents in Prevention of Maternal-Fetal Transmission of Hepatitis C Virus in Pregnancy.
Hartley C, Van T, Karnsakul W. Hartley C, et al. Pathogens. 2024 Jun 16;13(6):508. doi: 10.3390/pathogens13060508. Pathogens. 2024. PMID: 38921805 Free PMC article. Review. - Viral hepatitis management in pregnancy: practical insights from a pediatric perspective.
Rubino C, Stinco M, Indolfi G. Rubino C, et al. Transl Gastroenterol Hepatol. 2024 Apr 16;9:31. doi: 10.21037/tgh-23-109. eCollection 2024. Transl Gastroenterol Hepatol. 2024. PMID: 38716205 Free PMC article. No abstract available. - CDC's New Hepatitis C Virus Testing Recommendations for Perinatally Exposed Infants and Children: A Step Towards Hepatitis C Elimination.
Panagiotakopoulos L, Miele K, Cartwright EJ, Kamili S, Furukawa N, Woodworth K, Tong VT, Kim SY, Wester C, Sandul AL. Panagiotakopoulos L, et al. J Womens Health (Larchmt). 2024 Jun;33(6):695-701. doi: 10.1089/jwh.2023.1114. Epub 2024 Mar 13. J Womens Health (Larchmt). 2024. PMID: 38476092 Free PMC article. - Differences in Provider Hepatitis C Virus Screening Recommendations by Patient Risk Status.
Laily A, Duncan R, Gabhart KM, Nephew LD, Christy SM, Vadaparampil ST, Giuliano AR, Kasting ML. Laily A, et al. Prev Med Rep. 2024 Jan 9;38:102602. doi: 10.1016/j.pmedr.2024.102602. eCollection 2024 Feb. Prev Med Rep. 2024. PMID: 38375175 Free PMC article. - CDC Recommendations for Hepatitis C Testing Among Perinatally Exposed Infants and Children - United States, 2023.
Panagiotakopoulos L, Sandul AL; DHSc; Conners EE, Foster MA, Nelson NP, Wester C; Collaborators. Panagiotakopoulos L, et al. MMWR Recomm Rep. 2023 Nov 3;72(4):1-21. doi: 10.15585/mmwr.rr7204a1. MMWR Recomm Rep. 2023. PMID: 37906518 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources